Astellas Says It Aims for ‘Friendly’ Bid of CV Therapeutics As Q3 Profits Decline
This article was originally published in PharmAsia News
Executive Summary
TOKYO - An Astellas Pharma senior executive said during a Feb. 2 earnings call the company is aiming to make its bid for CV Therapeutics a friendly proposal rather than a hostile takeover